Since the early 2000s, unconventional natural gas development (UNGD) has rapidly grown throughout Pennsylvania. UNGD extracts natural gas using a relatively new method known as hydraulic fracturing (HF). Here we addressed the association of HF with asthma Hospitalization Admission Rates (HAR) using publicly available data. Using public county-level data from the Pennsylvania Department of Health (PA-DOH) and the Pennsylvania Department of Environmental Protection for the years 2001–2014, we constructed regression models to study the previously observed association between asthma exacerbation and HF. After considering multicollinearity, county-level demographics and area-level covariables were included to account for known asthma risk factors. We found a significant positive association between the asthma HAR and annual well density for all the counties in the state (3% increase in HAR attributable to HF, p<0.001). For a sensitivity analysis, we excluded urban counties (urban counties have higher asthma exacerbations) and focused on rural counties for the years 2005–2014 and found a significant association (3.31% increase in HAR attributable to HF in rural counties, p<0.001). An even stronger association was found between asthma hospitalization admission rates (HAR) and PM2.5 levels (7.52% increase in HAR attributable to PM2.5, p<0.001). As expected, asthma HAR was significantly higher in urban compared to rural counties and showed a significant racial disparity. We conclude that publicly available data at the county-level supports an association between an increase in asthma HAR and UNGD in rural counties in Pennsylvania.
Per- and polyfluoroalkyl substances (PFAS) may interact with peroxisome proliferator activated receptors (PPARs) and alter lipid homeostasis. Using Xenopus laevis, we investigated the effect of PFAS on (a) lipid homeostasis and whether this correlated to changes in body and hepatic condition; (b) the expression of hepatic genes regulated by PPAR; and (c) the hepatic lipidome. We chronically exposed tadpoles to 0.5 µg/L of either PFOS, PFHxS, PFOA, PFHxA, a binary mixture of PFOS and PFHxS (0.5 µg/L of each), or a control, from NF stage 52 through metamorphic climax. Growth, development, and survival were not affected, but we detected a sex-specific decrease in body condition at NF 66 (6.8%) and in hepatic condition (16.6%) across metamorphic climax for male tadpoles exposed to PFOS. We observed weak evidence for the transient downregulation of apolipoprotein-V (apoa5) at NF 62 in tadpoles exposed to PFHxA. Acyl-CoA oxidase 1 (acox1) was downregulated only in males exposed to PFHxS (Ln(Fold Change) = −0.54). We detected PFAS-specific downregulation of structural glycerophospholipids, while semi-quantitative profiling detected the upregulation in numerous glycerophospholipids, sphingomyelins, and diglycerides. Overall, our findings indicate that PFAS can induce sex-specific effects that change across larval development and metamorphosis. We demonstrate that PFAS alter lipid metabolism at environmentally relevant concentrations through divergent mechanisms that may not be related to PPARs, with an absence of effects on body condition, demonstrating the need for more molecular studies to elucidate mechanisms of PFAS-induced lipid dysregulation in amphibians and in other taxa.
3 September 2025 in Journal of Experimental Zoology Part A: Ecological and Integrative Physiology
Peroxisome proliferator‐activated receptors (PPAR) are master transcriptional regulators that maintain metabolic homeostasis in vertebrates. Amphibians are often exposed to endocrine disrupting compounds (EDCs) that could dysregulate lipid metabolism. Larvae of the African clawed frog ( Xenopus laevis ) are routinely used as a model to study aquatic EDC exposures, but PPAR expression has not been characterized across larval development or metamorphosis in this species. We conducted two experiments to elucidate (a) the expression in late metamorphosis for xPPAR α / β / γ subtypes, and (b) the effect of pharmaceutical PPAR agonists (pirinixic acid, bezafibrate, and ciprofibrate) on the expression of xPPAR α / β / γ target genes. Additionally, we considered apical endpoints (body mass, body condition [scaled mass index, SMI], and relative liver mass). We hypothesized pharmaceuticals would agonize hepatic xPPAR α / β / γ , upregulating expression of downstream target genes and reducing apical endpoints with variation reflective of developmental patterns of nuclear receptor expression. We observed upregulation of xPPAR α during late premetamorphosis (NF 51), prometamorphosis (NF 56–57), and metamorphic climax (NF 58–66), which also held for xPPAR γ with exception for peak of metamorphic climax (NF 62). For xPPAR β , we only observed upregulation at conclusion of metamorphic climax (NF 66). Agonists did not cause changes in gene expression for xPPAR α / β / γ targets, but pirinixic acid exposure decreased female body condition. The dynamic hepatic expression of xPPAR α / β / γ during late metamorphosis is presumably necessary to coordinate energy flux and highlights a potential period of susceptibility to PPAR agonism. However, pharmaceuticals identified to interact with xPPARα/β/γ did not elicit a response concordant with PPAR agonism at high doses. These results suggest that X. laevis may not be a sensitive model for studies testing PPAR‐mediated effects of xenobiotics.